secwatch.observer — SEC 8-K summary
======================================

Issuer:     DEXCOM INC (DXCM)
CIK:        0001093557
Form:       8-K
Filed at:   2024-10-24T23:59:59+00:00
Accession:  0001093557-24-000179
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dexcom Q3 revenue $994M (+2%); reiterates FY24 guidance; CCO retiring
---------------------------------------------------------------------

- Revenue $994.2M (+2% reported, +3% organic); U.S. down 2%, international up 12%.
- GAAP net income $134.6M ($0.34 EPS); Non-GAAP $179.9M ($0.45 EPS). Operating margin contracted.
- Launched Stelo OTC glucose biosensor in U.S.; Dexcom G7 in Australia, ONE+ in France.
- FY24 guidance reaffirmed: revenue ~$4.00-4.05B, non-GAAP operating margin ~20%.
- Teri Lawver, EVP & Chief Commercial Officer, retiring year-end; CEO Sayer leading commercial while search ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1093557/000109355724000179/0001093557-24-000179-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1093557/000109355724000179/dxcm-20241024.htm
  HTML page:      https://secwatch.observer/filing/0001093557-24-000179

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer